Amir Nashat is an entrepreneur partner at Polaris Partners, where he focuses on portfolio company executive roles as well as investing in healthcare companies. He joined Polaris in 2002 and also serves as a managing partner of Polaris Funds VI – IX.
Amir currently represents Polaris as a Director of AgBiome, CAMP4 Therapeutics, Dewpoint Therapeutics, and Paratus Sciences.
Additionally, Amir has served as a director of Adnexus Therapeutics (Bristol Myers Squibb), Athenix Corporation (Bayer), Avila Therapeutics (Celgene), Fate Therapeutics (NASDAQ: FATE), Freenome, Living Proof (Unilever), Metacrine Therapeutics, Morphic Therapeutic (Lilly), Primmune Therapeutics, Promedior Pharmaceuticals (Roche), Receptos (Celgene), Scholar Rock (NASDAQ: SRRK), Selecta Biosciences (NASDAQ: SELB), Sun Catalytix (Lockheed Martin), Syros Pharmaceuticals (NASDAQ: SYRS), and TARIS Biomedical (J&J). He was also CEO of Polaris portfolio companies Dewpoint, Jnana, Living Proof, Olivo Labs, Paratus Sciences, and Sun Catalytix.
Amir also serves on the Partners Innovation Fund and the Investment Advisory Committee for The Engine at MIT, and helped launch the MIT Sandbox Innovation Fund as its active president.
He has been named to the Forbes Midas List of “Top 100 Venture Capitalists” (2016).
Prior to joining Polaris, Amir completed his ScD as a Hertz Fellow in Chemical Engineering at the Massachusetts Institute of Technology with a minor in Biology under the guidance of Dr. Robert Langer. Amir also earned both his MS and BS in Materials Science and Mechanical Engineering at the University of California, Berkeley.
